Studies presented at the 2017 hepatology meeting in Washington, DC, sought to provide answers to questions surrounding mortality and HCC risk in patients with HCV who achieved SVR with DAA therapy. Here’s my take.
At AASLD 2017, exciting new data were presented on both current and investigational therapies for chronic HBV infection.
Here’s my take on how new data from AASLD 2017 on noninvasive imaging modalities and emerging investigational agents may affect the NAFLD/NASH patient management landscape.
How will data presented at AASLD 2017 on 8-week therapy have an impact on management of patients with HCV infection? Here’s my take.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.